Keywords: Adeona Pharma, Intrexon, PAH, Pulmonary arterial hypertension, Research collaboration

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy

Article | 22 November 2011

Print This

USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp have entered into a global ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in